Ampuero et al reported the Hepamet Fibrosis Scoring System to identify a patient with nonalcoholic fatty liver disease who has advanced fibrosis. The authors are from multiple institutions from Spain, France, Italy, the United States and China participating in the HEPAmet registry.
Patient selection: nonalcoholic fatty liver disease
Outcome: significant hepatic fibrosis (F3 or F4)
Parameters:
(1) age of the patient
(2) sex
(3) serum AST in IU/L
(4) serum albumin in g/dL
(5) homeostatic model assessment for insulin resistance (HOMA-IR)
(6) diabetes mellitus
(7) platelet count per microliter
Parameter
Finding
Points
age of the patient
< 45 years
0
45 to 64 years
0.986
>= 65
1.719
sex
female
0
male
-0.875
serum AST
< 35 IU/L
0
35 to 69 IU/L
0.896
>= 70 IU/L
2.126
serum albumin
>=4.5 g/dL
0
4.0 to 4.49 g/dL
0.027
< 4 g/dL
0.897
diabetes
no AND HOMA-IR < 2
0
no AND HOMA-IR 2.0 to 3.99
0.899
no AND HOMA-IR >= 4
1.497
yes
2.184
platelet count
>= 220,000 per µL
0
155,000 to 219,000 per µL
0.882
< 155,000 per µL
2.233
value of X =
= SUM(points for all 7 parameters) - 5.390
probability of advanced fibrosis =
= 1 / (1+ EXP((-1) * X))
Performance:
• The area under the ROC curve was 0.85.
Continue Reading
